Endometriosis Market

The Endometriosis Market size was valued at USD 1.52 Billion in 2024 and the total Endometriosis revenue is expected to grow at a CAGR of 12.6% from 2025 to 2032, reaching nearly USD 3.93 Billion.

The Endometriosis Market refers to the industry involved in the development, production, and distribution of products for the treatment of endometriosis. Endometriosis is a medical condition that occurs when tissue similar to the endometrium grows outside of the uterus, such as on the ovaries, fallopian tubes, and surrounding tissues in the pelvis and abdomen. It is categorized into four types based on the affected area: superficial peritoneal endometriosis, endometriomas, deeply infiltrating endometriosis, and abdominal wall endometriosis. Various treatments are available for endometriosis, including oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines, aromatase inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs).

The Endometriosis Market is driven by increasing disease burden, rising disease awareness, and robust product pipeline. However, the industry also faces competition from generic and off-label products, which may impede its growth. In the global population of reproductive-age females with endometriosis was approximately 190 million, representing about 10% of the female population. Despite the high prevalence, healthcare workers report delays in diagnosis due to the broad and variable symptoms of endometriosis. This delay in diagnosis exacerbates symptoms, increasing the need for treatment and contributing to limited awareness of the condition.To know about the Research Methodology :- Request Free Sample Report

Competitive Landscapes:

The Endometriosis Market is moderately competitive, with leading companies holding a majority share of the market. However, the forecast period is expected to see an increase in new entrants, which could make the market increasingly competitive. Key players in the endometriosis treatment market are undertaking strategic initiatives such as new launches, collaborations, mergers, and acquisitions, which are further driving market growth. For Instance, in February , Theramex and ObsEva SA announced a strategic licensing agreement to support the commercialization and expansion of Linzagolix across the global market. This strategic initiative is expected to strengthen the position of these key players in the market.

The regulatory approvals for products are a significant contributor to competitive advantage for players in the Endometriosis Market. In August , Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) had approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the once-daily treatment of moderate-to-severe endometriosis-associated pain. This approval is an important milestone reflecting Pfizer and Myovant's commitment to women's health in areas of significant unmet need.Similarly, in June , Genes2Me Pvt. Ltd., a leading IVD solution manufacturer in India, launched CoviEasy, a self-test rapid antigen test kit for COVID-19 that delivers faster results in 10 minutes and is easy to use. Backed by an AI-driven mobile app, this IVD product provides a high level of sensitivity and concordance, with more than 98% accuracy.

These product launches and advancements in technology by major players in the at-home testing market indicate the intensity of industry rivalry and the need for innovation to stay competitive. The market is expected to continue to witness high competition in the forecast period, as companies strive to capture a larger market share through new product launches, strategic partnerships, and mergers and acquisitions

Endometriosis Market Dynamics:

Increasing Public Awareness Initiatives are driving the Endometriosis Market growth during the forecast period

Endometriosis awareness programs occur annually across various countries globally to raise awareness about the disease. These initiatives include conferences and virtual forums where experts discuss the myths and facts associated with endometriosis. For example, on March 12th, Austria hosted a free full-day online congress that provided knowledge from experts on endometriosis.

Similarly, on March 19th and 20th,  the Endometriosis and Reproductive Health Foundation in Bulgaria organized a virtual conference called "Myths and Truths About the Disease" to discuss common myths associated with the disease. Other countries, including Canada, Bangladesh, Finland, France, Hungary, and India, have also raised a series of activities to encourage open discussion about endometriosis.

Such initiatives are expected to drive the endometriosis treatment market during the forecast period, as they increase public awareness and understanding of the disease. The government and key market players are also actively investing in research and development and increasing funds to further cater to market growth. For example, in March , the U.S. federal government announced USD 92 million funds to the National Institute of Child Health and Human Development (NICHD) for endometriosis research. Similarly, in February , DBT Wellcome India Alliance announced a grant of USD 0.47 million for the Endometriosis Clinical and Genetic Research in India (ECGRI) project, which aims to conduct an endometriosis clinical study on genetic risks and phenotypes associated with the disease

Continuous R&D for Advanced Drug Technology Driving Growth in the Endometriosis Market

The Endometriosis Therapeutics Market is expected to experience significant growth due to the evolution of methods and drugs as a result of technological advancement. Market players are proposing novel drug delivery technologies, such as topical applicators, to overcome the side effects of oral contraceptives and improve efficiency, as many women sufferings from endometriosis increase the demand for treatment. . The industry is responding to market requirements by proposing novel drug delivery technologies to improve treatment efficiency and reduce side effects. The introduction of new products with improved pharmacological profiles and delivery systems is driving the growth of the industry.

For instance, in  Astellas Pharma Inc. announced the outcome of the clinical trial version Phase 3 for their non-hormonal composite, "SKYLIGHT 4", which is being studied for treating sensible to severe vasomotor symptoms associated with menopause (VMS). This advancement will encourage future regulatory organizing submissions. In the Endometriosis industry, research and development are essential components of growth and competitiveness. Continuous investment in research and development by key market players is driving the development of advanced drug technology for the treatment of endometriosis. This has enabled the introduction of new products with higher efficiency, improved safety profiles, and fewer side effects. As a result, there is an increased focus on research and development of drugs with improved pharmacological profiles and delivery systems.

Endometriosis Market Segment Analysis:

Based on treatment type, the endometriosis market is segmented into Pain Medication Hormone Therapy. According to the segment analysis of the Endometriosis Market, the pain medication segment accounted for a highest Market Share in 2024. This segment is driven by the need to alleviate the painful symptoms experienced by endometriosis patients, including dysmenorrhea, dyspareunia, chronic pelvic pain, infertility, and psychological distress. Medications that can effectively suppress these painful symptoms have fewer side effects, reasonable costs, good tolerance, and high safety profiles, leading to an increase in their demand. NSAIDs, such as ibuprofen, paracetamol, and naproxen, are the most commonly prescribed pain medications for endometriosis patients.On the other hand, the hormone therapy segment is expected to witness a CAGR of 13.99% during the forecast period. Hormone therapy includes prominent therapeutic products such as the Relugolix combination tablet from Myovant/Pfizer and Yselty (linzagolix) from ObsEva, which are expected to drive the growth of this segment. Strategic collaborations between key players in the market are also expected to boost market growth. For example, in February 2024, ObsEva SA and Theramex entered into a strategic licensing agreement to expand the use of linzagolix outside of the U.S., Canada, and Asia. Linzagolix has shown potential as a treatment for endometriosis-associated pain.

By Drug Class, the endometriosis market is segmented into NSAIDs, Oral Contraceptive, Gonadotropin Releasing Hormone and Others. In 2024, the NSAIDs segment accounted for a significant share of 19.50% in the Endometriosis market. The immediate pain relief effects and their availability as both over-the-counter and prescription drugs at a reasonable cost with NSAIDS is driving the segment growth. Nonsteroidal anti-inflammatory drugs such as paracetamol, ibuprofen and naproxen work by blocking the production of prostaglandins and are effective in reducing mild to moderate pain.

Over the forecast period, the Gonadotropin-releasing hormone (GnRH) medicines segment is expected to dominate the Endometriosis market. Available in various forms such as pills, shots, injections, or nasal sprays, these medicines are prescribed to treat pain associated with the disease. AbbVie Inc.’s Orilissa (elagolix) was the first pill approved by the FDA for this purpose. GnRH agonists and antagonists such as Zoladex, Lupron, Orilissa and Synarel are used as an alternative treatment for patients who are resistant to first-line treatment. One major advantage of this treatment is that after completion, patients return to a normal menstrual cycle and their ability to conceive is not affected.

Based on route of administration, the endometriosis market is segmented into Oral, Injectable & others. In 2024, the oral route of administration was the dominant segment in the Endometriosis Market, accounting for a revenue share of 19.7%. This segment is expected to maintain its share over the forecast period due to its common and convenient route of administration for painkillers, good bioavailability, and effectiveness for hormone therapy. The oral route of administration includes NSAIDs, oral contraceptives, oral progestins such as Aygestin and Provera, and oral GnRH agonists, which are driving the segment growth. The introduction of AbbVie's Orilissa (elagolix), the first orally administered GnRH antagonist for the management of endometriosis, is fueling the segment.

On the other hand, the other route of administration is expected to witness a CAGR of 5.35% during the forecast period. This growth can be attributed to the presence of topical formulations as novel transdermal drug delivery technologies, which demonstrate increased efficacy by bypassing first-pass metabolism. The segment includes contraceptive patches such as Twirla and Xulane. Furthermore, key players are showing interest in developing such a transdermal system, which is boosting the segment growth. For example, Noven Pharmaceuticals has developed CombiPatch, which is a combination patch (estradiol/norethindrone acetate) for the treatment of endometriosis.

By Distribution Channel, the endometriosis market is segregated into retail pharmacies, hospital pharmacies and others. The distribution channel segment analysis of the Endometriosis Market reveals that the retail pharmacy segment held the largest revenue share of 67.4% in 2024. This can be attributed to the fact that most endometriosis patients receive treatment in outpatient settings and over-the-counter drugs are readily available at retail pharmacies. Moreover, factors such as the rising volume of prescriptions for endometriosis drugs, growing awareness of the disease, and increasing healthcare expenditure are driving the Endometriosis market growth in this segment.On the other hand, the hospital pharmacy segment is expected to experience moderate growth during the forecast period. The rising preference for surgery as an endometriosis treatment option in a hospital setting is a major driver for this segment. Additionally, hospital pharmacists, as medication experts, can assist patients with endometriosis and their caregivers in selecting appropriate medications, thereby supporting segment growth.

Endometriosis Market Regional Insights:

The global endometriosis market is studied across various regions, including North America, Europe, Asia-Pacific, and LAMEA. North America holds the largest market share and is expected to maintain its dominance during the forecast period. This is due to the presence of major players such as Abbott Laboratories, Merck & Co. Inc., and Pfizer Inc., as well as advancements in manufacturing technology for medicines. The surge in incidences of endometriosis that require treatment with gonadotropin-releasing hormone (GnRH) medicines, along with funding from governments for research regarding endometriosis treatment, and a significant rise in capital income in developed countries, also contribute to the growth of the market.

The sophisticated reimbursement structure in North America, aimed at reducing expenditure levels, is another factor that drives market growth. The United States is anticipated to contribute to a major share of the regional market and is expected to drive the growth of the endometriosis market throughout the forecast period. The presence of a well-established healthcare infrastructure, high purchasing power, and a rise in the adoption rate of endometriosis medicine are expected to drive market growth in the US.

On the other hand, the Asia-Pacific region is expected to experience the highest growth rate during the endometriosis market forecast period. This growth is attributed to the increase in the number of endometriosis cases in the region, as well as the growth in purchasing power of highly populated countries, such as China and India. These countries have a huge population base, with China being the most populated country in the world with 1,397,715 population in and India being the second most populated country with 1,366,417.75 population in . As a result, this presents significant growth opportunities for the endometriosis market in the Asia-Pacific region.

Endometriosis Market Scope: Inquire before buying

Endometriosis Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Endometriosis Market Key Players:

1. Bayer AG
2. Pfizer, Inc.
3. AbbVie, Inc
4. AstraZeneca;
5. ObsEva SA;
6. Teva Pharmaceutical Industries
7. Zydus Healthcare Limited;
8. Eli Lilly and Company
9. Astellas Pharma Inc
10. Consilient Health Limited,
11. Serum Institute of India Pvt. Ltd.
12. Abbott Laboratories
13. GlaxoSmithKline plc,
14. Merck & Co. Inc.,
15. Sanofi
16. Sun Pharmaceutical Industries Ltd
17. Torrent Pharmaceuticals Ltd
18. Lanett
19. TerSera Therapeutics USA
20. Tolmar Pharmaceuticals, Inc

FAQs:

1] What segments are covered in the Global Endometriosis Market report?
Ans. The segments covered in the Endometriosis report are based on Treatment type, Drug Class, Route of Administration Distribution Channel and region.

2] Which region is expected to hold the highest share in the Global Endometriosis Market during the forecast period?
Ans. The North America region is expected to hold the highest share of the Endometriosis market during the forecast period.

3] What is the market size of the Global Endometriosis by 2032?
Ans. The market size of the Endometriosis by 2032 is expected to reach USD 3.93 Bn.

4] What is the forecast period for the Global Endometriosis Market?
Ans. The forecast period for the Endometriosis market is 2025-2032.

5] What was the Global Endometriosis Market size in 2024?
Ans: The Global Endometriosis Market size was USD 1.52 Billion in 2024.